Regulation - Roche, Neurological

Filter

Current filters:

RocheNeurological

Popular Filters

Positive recommendations from EMA's CHMP for Selincro, Adasuve and Perjeta

17-12-2012

Last week's deliberations of the European Medicines Agency's Committee for Medicinal Products for Human…

AdasuveAlexza PharmaceuticalBiotechnologyEuropeFerrer InternacionalLundbeckNeurologicalOncologyPerjetaPharmaceuticalRegulationRocheSelincro

Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya

11-09-2012

Swiss drug major Roche (ROG SIX) says it is "extremely disappointed" that the Scottish Medicines Consortium…

EuropeGilenyaHealthcareNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRocheZelboraf

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

UK NICE says Novartis MS drug Gilenya not cost effective, but backs extended use of Roche’s MabThera

01-12-2011

In further draft guidance published today (December 1), UK drugs watchdog the National Institute for…

EuropeGilenyaMabTheraNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRoche

Back to top